NEW YORK (GenomeWeb News) – Meridian Bioscience today reported essentially flat year-over-year sales growth for the second quarter, though adoption of its molecular diagnostic platform continued to accelerate.

For the three months ended March 31, revenues came in at $47.3 million, up a fraction of 1 percent from $47.2 million a year ago, and missing the average analyst estimate of $49.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.